Key Viral Hepatitis Studies Influencing My Practice Following EASL 2022—Audio Recap

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from EASL 2022, including:

• Novel HBV therapeutics, including the REEF-2, B-Clear, and SAVE-1 studies
• HBV cure from the Everest Project in China
• HDV therapeutics from MYR301 and a study of bulevirtide in patients with cirrhosis and portal hypertension
• HCV retreatment in patients with prior direct-acting antiviral therapy failure

Presenter: 

Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I 
JW Goethe University Hospital 
Frankfurt, Germany

Follow along with the downloadable slideset at:
https://bit.ly/3yJAruD

Link to full program: 
https://bit.ly/3AjCNBC

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.